Gretchen Poortinga

3.6k total citations
31 papers, 2.0k citations indexed

About

Gretchen Poortinga is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Gretchen Poortinga has authored 31 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Gretchen Poortinga's work include Genomics and Chromatin Dynamics (10 papers), RNA modifications and cancer (8 papers) and Ubiquitin and proteasome pathways (7 papers). Gretchen Poortinga is often cited by papers focused on Genomics and Chromatin Dynamics (10 papers), RNA modifications and cancer (8 papers) and Ubiquitin and proteasome pathways (7 papers). Gretchen Poortinga collaborates with scholars based in Australia, United States and Spain. Gretchen Poortinga's co-authors include Ross D. Hannan, Grant A. McArthur, Richard B. Pearson, Katherine M. Hannan, Susan M. Parkhurst, Kerith Sharkey, Meaghan Wall, Elaine Sanij, Tom Moss and Yves Brandenburger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Gretchen Poortinga

30 papers receiving 2.0k citations

Peers

Countries citing papers authored by Gretchen Poortinga

Since Specialization

Citations

This map shows the geographic impact of Gretchen Poortinga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gretchen Poortinga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gretchen Poortinga more than expected).

Fields of papers citing papers by Gretchen Poortinga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gretchen Poortinga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gretchen Poortinga. The network helps show where Gretchen Poortinga may publish in the future.

Co-authorship network of co-authors of Gretchen Poortinga

This figure shows the co-authorship network connecting the top 25 collaborators of Gretchen Poortinga. A scholar is included among the top collaborators of Gretchen Poortinga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gretchen Poortinga. Gretchen Poortinga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting the ribosome to treat multiple myeloma 2024 ·SHILAP Revista de lepidopterología ·Kylee Maclachlan, (unknown), Jian Kang, Andrew Cuddihy, (unknown), Nadine Hein, Carleen Cullinane, Ching‐Seng Ang, Natalie Brajanovski, Richard B. Pearson, Amit Khot, Elaine Sanij, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison	6
2	CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci 2024 ·Biomedicines ·Donald P. Cameron, (unknown), (unknown), Denis Drygin, Gretchen Poortinga, Grant A. McArthur, Nadine Hein, Ross D. Hannan, Kostya I. Panov	4
3	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis 2020 ·The EMBO Journal ·Eric Kusnadi, Anna Trigos, Carleen Cullinane, David L. Goode, Ola Larsson, Jennifer R. Devlin, Keefe T. Chan, David P. De Souza, Malcolm J. McConville, Grant A. McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D. Hannan, Katherine M. Hannan, Jian Kang, Richard B. Pearson	28
4	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461 2020 ·Frontiers in Cell and Developmental Biology ·Jinbae Son, Katherine M. Hannan, Gretchen Poortinga, Nadine Hein, Donald P. Cameron, Austen R. D. Ganley, Karen E. Sheppard, Richard B. Pearson, Ross D. Hannan, Elaine Sanij	17
5	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study 2019 ·Cancer Discovery ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John K. C. Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison	132
6	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation 2019 ·Communications Biology ·Jeannine Diesch, Megan J. Bywater, Elaine Sanij, Donald P. Cameron, William Schierding, Natalie Brajanovski, Jinbae Son, (unknown), Nadine Hein, M. Evers, Richard B. Pearson, Grant A. McArthur, Austen R. D. Ganley, Justin M. O’Sullivan, Ross D. Hannan, Gretchen Poortinga	32
7	Novel Combination Therapies with the RNA Polymerase I Inhibitor CX-5461 Significantly Improve Efficacy in Multiple Myeloma 2017 ·Blood ·Kylee Maclachlan, Andrew Cuddihy, Nadine Hein, Carleen Cullinane, Simon J. Harrison, Ross D. Hannan, Gretchen Poortinga	3
8	RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study 2017 ·Blood ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Gretchen Poortinga, Elaine Sanij, (unknown), John Soong, Nadine Hein, Emma Link, Richard B. Pearson, Ross D. Hannan, Grant A. McArthur, Simon J. Harrison	2
9	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling 2016 ·Oncotarget ·Jaclyn Quin, Keefe T. Chan, Jennifer R. Devlin, Donald P. Cameron, Jeannine Diesch, Carleen Cullinane, Jessica Ahern, Amit Khot, Nadine Hein, Amee J. George, Katherine M. Hannan, Gretchen Poortinga, Karen E. Sheppard, Kum Kum Khanna, Ricky W. Johnstone, Denis Drygin, Grant A. McArthur, Richard B. Pearson, Elaine Sanij, Ross D. Hannan	79
10	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma 2015 ·Cancer Discovery ·Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J. George, Jake Shortt, Megan J. Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O’Brien, Ricky W. Johnstone, Grant A. McArthur, Ross D. Hannan, Richard B. Pearson	91
11	Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models 2015 ·Nature Communications ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Linda M. Parsons, Gretchen Poortinga, David Levens, Ross D. Hannan, Leonie M. Quinn	10
12	S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila 2015 ·Cellular Signalling ·(unknown), (unknown), (unknown), (unknown), (unknown), Jane I. Lin, Linda M. Parsons, Katarzyna Jastrzebski, Gretchen Poortinga, Katherine M. Hannan, Richard B. Pearson, Ross D. Hannan, Leonie M. Quinn	14
13	A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes 2014 ·Genome Research ·Elaine Sanij, Jeannine Diesch, (unknown), Gretchen Poortinga, Nadine Hein, Grace E. Lidgerwood, Donald P. Cameron, Jason Ellul, Gregory J. Goodall, Lee H. Wong, Amardeep S. Dhillon, Nourdine Hamdane, Lawrence I. Rothblum, Richard B. Pearson, Izhak Haviv, Tom Moss, Ross D. Hannan	45
14	Abstract 2735: Multi-point targeting of the synthetic lethal interactions between Myc, ribosome biogenesis and ribosome function cooperates to treat B-cell lymphoma 2014 ·Cancer Research ·Richard B. Pearson, Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein, Megan J. Bywater, Gretchen Poortinga, Donald P. Cameron, Denis Drygin, Sean O’Brien, Carleen Cullinane, Grant A. McArthur, Ross D. Hannan	1
15	Targeting RNA polymerase I to treat MYC-driven cancer 2014 ·Oncogene ·Gretchen Poortinga, Leonie M. Quinn, Ross D. Hannan	65
16	The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence 2012 ·Cancer Discovery ·Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone, Grant A. McArthur	52
17	c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation 2010 ·Nucleic Acids Research ·Gretchen Poortinga, Meaghan Wall, Elaine Sanij, (unknown), Jason Ellul, Daniel V. Brown, Timothy P. Holloway, Ross D. Hannan, Grant A. McArthur	76
18	MAD1 and c‐MYC regulate UBF and rDNA transcription during granulocyte differentiation 2004 ·The EMBO Journal ·Gretchen Poortinga, Katherine M. Hannan, (unknown), Carl R. Walkley, Anna Jenkins, Kerith Sharkey, Meaghan Wall, Yves Brandenburger, Manuela Palatsides, Richard B. Pearson, Grant A. McArthur, Ross D. Hannan	147
19	A network of interacting transcriptional regulators involved in Drosophila neural fate specification revealed by the yeast two-hybrid system 1997 ·Proceedings of the National Academy of Sciences ·Pavlos Alifragis, Gretchen Poortinga, Susan M. Parkhurst, Christos Delidakis	69
20	Tryptophan analog resistance mutations in Chlamydomonas reinhardtii. 1992 ·Genetics ·Susan K. Dutcher, (unknown), (unknown), Gretchen Poortinga	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact